• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Cybin Inc.

    6/11/26 2:34:35 PM ET
    $HELP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HELP alert in real time by email
    6-K 1 cybininc-form6xk06x11x2026.htm 6-K Document

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    Form 6-K

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    For the month of June, 2026.
    Commission File Number: 001-40673


    Cybin Inc.
    (Exact Name of Registrant as Specified in Charter)

    100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9
    (Address of principal executive offices)

    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
    Form 20-F □ Form 40-F ⊠






    SIGNATURE
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
    CYBIN INC.
    (Registrant)
     
    Date:June 11, 2026By:
    /s/ Greg Cavers    
    Name:Greg Cavers
    Title:Chief Financial Officer





    EXHIBIT INDEX

    99.1
    News Release dated June 11, 2026

    Get the next $HELP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HELP

    DatePrice TargetRatingAnalyst
    4/13/2026$8.00Buy
    TD Cowen
    2/2/2026$22.00Buy
    Jefferies
    More analyst ratings

    $HELP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Helus Pharma™ Announces US$50 Million Underwritten Offering

    NEW YORK and TORONTO, June 24, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (NASDAQ:HELP) (Cboe CA: HELP) (the "Company" or "Helus Pharma"), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists ("NSAs"), is pleased to announce the pricing of an underwritten offering of 10,309,280 common shares in the capital of the Company (the "Common Shares") at an offering price of US$4.85 per Common Share, for aggregate gross proceeds of US$50 million (the "Offering"). Cantor and Barclays are acting as joint bookrunning managers for the Offering. Bloom Burton Securities Inc. and Lucid Capital Markets are acting as lead managers for the Offering.

    6/24/26 6:01:00 AM ET
    $HELP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Helus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progress

    - APPROACH Phase 3 clinical trial of HLP003 for the adjunctive treatment of major depressive disorder ("MDD") is progressing as planned and has surpassed 86% enrollment - - Phase 2 HLP003 data demonstrated long-term efficacy with ~23-point reduction in Montgomery-Asberg Depression Rating Scale ("MADRS") score compared to baseline at 12 months after two 16 mg doses of HLP003 three weeks apart -  - Previously reported Phase 2 HLP003 results showed response and remission rates of 75% at week 18 and by the 12-month mark, response and remission rates improved to 100% and 71% respectively - - Previously granted Breakthrough Therapy Designation for HLP003 by the FDA - - Company remains on track

    6/24/26 6:00:00 AM ET
    $HELP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Helus Pharma to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Conference

    NEW YORK and TORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Helus PharmaTM (NASDAQ:HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists ("NSAs"), today announced that Amir Inamdar, Helus Pharma's Chief Medical Officer, will participate in a fireside chat at the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference taking place June 15-16, 2026. The fireside chat will be available on demand beginning on Monday, June 15 at 7:00 a.m. EDT. To register for the webcast, click here. A replay will be available on the Events & Presentations page of Helus Pharma's investor relations website. About Helus Phar

    6/11/26 7:30:00 AM ET
    $HELP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HELP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TD Cowen initiated coverage on Helus Pharma with a new price target

    TD Cowen initiated coverage of Helus Pharma with a rating of Buy and set a new price target of $8.00

    4/13/26 8:52:11 AM ET
    $HELP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies initiated coverage on Helus Pharma with a new price target

    Jefferies initiated coverage of Helus Pharma with a rating of Buy and set a new price target of $22.00

    2/2/26 6:51:26 AM ET
    $HELP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HELP
    SEC Filings

    View All

    SEC Form FWP filed by Cybin Inc.

    FWP - CYBIN INC. (0001833141) (Subject)

    6/23/26 8:05:10 PM ET
    $HELP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Cybin Inc.

    6-K - CYBIN INC. (0001833141) (Filer)

    6/11/26 2:34:35 PM ET
    $HELP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Cybin Inc.

    6-K - CYBIN INC. (0001833141) (Filer)

    6/1/26 5:24:14 PM ET
    $HELP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HELP
    Leadership Updates

    Live Leadership Updates

    View All

    Helus Pharma Strengthens Medical Leadership by Appointing Dr. Ken Kramer as Senior Vice President, Medical Affairs

    Dr. Kramer's 25 years' of experience in neuroscience and proven track record leading global medical launch neuropsychiatry teams will strengthen scientific and clinical engagement NEW YORK and TORONTO, April 16, 2026 (GLOBE NEWSWIRE) -- Helus PharmaTM (NASDAQ:HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists ("NSAs"), today announced the appointment of Dr. Ken Kramer, PhD as Senior Vice President, Medical Affairs, effective immediately. Dr. Kramer joins Helus with more than two decades of experience leading medical affairs strategy across neuroscience programs, including global launch readiness, eviden

    4/16/26 7:30:00 AM ET
    $HELP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer

    Proven human resources and organizational strategist brings more than two decades of leadership across the pharmaceutical industryAppointment supports Helus Pharma's continued maturation as the company advances its novel clinical pipeline NEW YORK and TORONTO, March 12, 2026 (GLOBE NEWSWIRE) -- Helus PharmaTM (NASDAQ:HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists ("NSAs"), today announced the appointment of Jill Conwell as Chief People Officer, effective immediately. Conwell brings more than two decades of leadership experience in the life sciences industry, with expertise spanning organizational st

    3/12/26 7:30:00 AM ET
    $HELP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee

    In this role, Dr. Lewis-Hall will guide clinical development strategy, regulatory engagement, and translational rigor across Helus' novel serotonergic agonist ("NSA") portfolio This news release constitutes a "designated news release" for the purpose of the Company's prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025. NEW YORK and TORONTO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (NASDAQ:HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company developing NSAs for serious mental health conditions, today announced the appointment of Dr. Freda Lewis-Hall, DFAPA, MFPM, to its Board of Di

    2/24/26 7:45:00 AM ET
    $HELP
    Biotechnology: Pharmaceutical Preparations
    Health Care